Follistatin-344
Gene-therapy mismatch · No established human dosing schedule
Follistatin-344 gene-transfer research is not evidence for dosing a vial of follistatin protein. Gene-therapy mismatch · No established human dosing schedule.
Reviewed 2026-10-17. A source reference, not a personal treatment plan. Discuss treatment decisions with a qualified clinician.
Dose reference
| STUDY CONTEXT | Dose | Frequency | Context |
|---|---|---|---|
| Human dosing | Not established | No validated schedule | Vector genomes cannot be converted into milligrams of recombinant protein. The study does not establish a human injection schedule for a follistatin-344 research vial. Source |
Vector genomes cannot be converted into milligrams of recombinant protein. The study does not establish a human injection schedule for a follistatin-344 research vial.
Source context
Mendell and colleagues delivered a viral vector carrying a follistatin construct into muscle. The intervention is a gene-transfer product whose dose is expressed in vector genomes.
Reading the dose correctly
Vector genomes cannot be converted into milligrams of recombinant protein. The study does not establish a human injection schedule for a follistatin-344 research vial.
Download the chart
Further reading
Follistatin-344 monograph on myPeptides
References
Why is there no numerical dose for Follistatin-344 on this card?
Vector genomes cannot be converted into milligrams of recombinant protein. The study does not establish a human injection schedule for a follistatin-344 research vial.
Does a missing dose mean that no research exists?
This card describes gene-therapy mismatch. Evidence of a mechanism, a laboratory finding or an exposure does not by itself establish a useful and safe human treatment schedule. The monograph explains the distinction.